Drugmakers See Innovation Justifying Further Price Rises

As U.S. consumers are asked to shoulder more prescription drug costs, drugmakers say prices for brand-name medicines will keep rising, mainly because use of their products reduces other healthcare costs.
Published Online: January 22, 2014

As U.S. consumers are asked to shoulder more prescription drug costs, drugmakers say prices for brand-name medicines will keep rising, mainly because use of their products reduces other healthcare costs.

Switzerland-based Roche Holding AG has a growth rate above the industry average due to its "high-quality" products that command "better prices, with fewer price cuts," Chief Financial Officer, Alan Hippe said, speaking at the annual JP Morgan Healthcare Conference in San Francisco earlier this week.

As long as Roche, maker of drugs like Herceptin for breast cancer, can prove that its new therapies work better than existing drugs, it can maintain pricing trends, Hippe said.

The company's leukemia drug Gazyva, priced at around $41,000 for a course of therapy, was the first to receive approval last year under a new U.S. regulatory program for "breakthrough" therapies that show promise in early testing. The Food and Drug Administration launched the pathway in response to scientific advances, especially targeted therapies designed to work for those with certain genetic mutations.

Read the full story here:http://reut.rs/1anjOpA

Source: Reuters

Feature
Recommended Articles
Dana Goldman, PhD, suggests that value for breakthrough therapies is most often associated with health benefits, health economics, and outcomes research; however, there are other sources of value that have not been taken into account yet.
The deal combines Humana's 3.2 million Medicare enrollees with Aetna's 1.26 million Medicare enrollees, giving the new combined company a strong position as the baby boomer population ages.
As co-pays and deductibles in Medicare and commercial health plans become more prevalent, so, too, does the temptation to waive them. But beware.
In addition to increasing insurance coverage, the Affordable Care Act also aims to improve population health and lower healthcare costs. However, not much attention has been paid to the quality of care the newly insured are receiving.
The UK government has come up with an innovative plan to increase public awareness of the increasing price of prescription drugs and what it costs the healthcare system